Trading Tips Blog

Kathryn Hayley, a director at Concentrix Corp (CNXC), recently bought 500 shares. The buy increased her stake by 6%, and came to a total cost of $25,110. This marks the first buy since last April, when multiple insiders bought shares, including the company CEO for nearly $50,000. Those insider buys occurred at far higher prices than where shares trade today. Otherwise, one company EVP has been a steady seller of shares over the past year. Overall, Concentrix insiders own 14.3% of ...
Read More About This

Oil giant BP (BP) has popped higher nearly 10% in the past month, as oil prices have jumped higher. One trader sees shares pulling back in the months ahead. That’s based on the March 21 $28 puts. With 52 days until expiration, 14,054 contracts traded compared to a prior open interest of 307, for a 46-fold rise in volume on the trade. The buyer of the puts paid $0.37 to make the bearish bet. BP shares recently traded close to $31.50, so ...
Read More About This

The stock market is back re-testing all-time highs. But while the overall market is back, several individual stocks are still well off their highs. Some are down for fundamental reasons. Others are simply taking a breather, and could be set to trend higher. And a few have been beaten down on news events but are likely to report strong earnings in the weeks ahead. Of the big-cap tech names, there’s been a notable laggard in recent months. Consumer tech giant Apple (AAPL) ...
Read More About This

Kyle Gendreau, a director at Caleres (CAL), recently bought 5,000 shares. The buy is a new stake for the director, who paid $99,661 for the stake. This marks the first insider buy in nearly six years, since the company President and CEO bought 2,000 shares. Otherwise, company insiders have been slight sellers of shares over the past two years, with the company’s Executive Chair selling a hefty stake. Overall, Caleres insiders own 3.2% of shares. The footwear retailer is down 37% over ...
Read More About This

Pharmaceutical giant Pfizer (PFE) has traded weakly in the past year, with shares down 7%. One trader sees further downside over the coming weeks. That’s based on the February 21 $24.50 puts. With 25 days until expiration, 38,679 contracts traded compared to a prior open interest of 194, for a massive 199-fold increase in volume on the trade. The buyer of the puts paid $0.24 to make the bearish bet. Pfizer shares recently traded close to $26.50, so the stock would need ...
Read More About This

Stocks got a jolt earlier this week, as President Trump announced that up to $500 billion will be invested in the years ahead to build up AI infrastructure in the United States. Several companies are part of that initiative, which will allow the U.S. to maintain its global lead. CEOs of several major tech companies made the announcement with Trump at the White House, including Sam Altman, CEO of OpenAI, which kicked off the AI revolution. The most likely winner on this ...
Read More About This

Kevin Johnson, a director at Goldman Sachs (GS), recently bought 2,400 shares. The buy is a new stake for the director, and came to a total cost of $1,485,648. That’s the first insider buy since March 2022, when another company director bought 82 shares for just under $30,000. Otherwise, there have been over two dozen insider sales over the past year, including the company CEO and CFO. Most sales have been direct sales, not a result of exercising stock options. Overall, Read More About This

Single-family home leasing company Invitation Homes (INVH) is down 6% over the past year, amid a softening market for rents and stubbornly-high interest rates. One trader sees shares trending higher in the months ahead. That’s based on the July $35 calls. With 175 days until expiration, 5,343 contracts traded compared to a prior open interest of 105, for a 51-fold rise in volume on the trade. The buyer of the calls paid $0.65 to make the bullish bet. Invitation Homes shares recently ...
Read More About This